Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Geoff Hale

Showing results (31-40 of 52) with videos related to

Pageof 6
Sort By:
Mabs|January 13, 2010
Preclinical development of monoclonal antibodies: considerations for the use of non-human primatesKathryn Chapman, Nick Pullen, Lee Coney, et al.
Blood|July 19, 2003
Reconstitution of the Epstein-Barr virus-specific cytotoxic T-lymphocyte response following T-cell-depleted myeloablative and nonmyeloablative allogeneic stem cell transplantationSuparno Chakrabarti, Donald W Milligan, Deenan Pillay, et al.
Journal of Neurology|July 27, 2005
The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapyAlasdair J Coles, Amanda Cox, Emmanuelle Le Page, et al.
Journal of Clinical Pharmacology|February 12, 2010
Pharmacokinetics and antibody responses to the CD3 antibody otelixizumab used in the treatment of type 1 diabetesGeoff Hale, Peppy Rebello, Ibrahim Al Bakir, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 30, 2003
Reduced-intensity transplantation with in vivo T-cell depletion and adjuvant dose-escalating donor lymphocyte infusions for chemotherapy-sensitive myeloma: limited efficacy of graft-versus-tumor activityKarl S Peggs, Stephen Mackinnon, Catherine D Williams, et al.
Haematologica|November 4, 2006
Outcomes after myeloablative unrelated donor stem cell transplantation using both in vitro and in vivo T-cell depletion with alemtuzumabPeter A von dem Borne, Floor Beaumont, C W J Ingrid Starrenburg, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 3, 2004
Incidence and outcome of adenovirus disease in transplant recipients after reduced-intensity conditioning with alemtuzumabIrit Avivi, Suparno Chakrabarti, Donald W Milligan, et al.
Blood|April 20, 2004
Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administrationGeoff Hale, Peppy Rebello, Lee R Brettman, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 1, 2004
Favorable effect on acute and chronic graft-versus-host disease with cyclophosphamide and in vivo anti-CD52 monoclonal antibodies for marrow transplantation from HLA-identical sibling donors for acquired aplastic anemiaVikas Gupta, Sarah E Ball, Qi-long Yi, et al.
British Journal of Haematology|December 11, 2002
Respiratory virus infections in transplant recipients after reduced-intensity conditioning with Campath-1H: high incidence but low mortalitySuparno Chakrabarti, Irit Avivi, Stephen Mackinnon, et al.
Pageof 6

Showing results (31-40 of 52) with videos related to

Sort By:
Pageof 6
Mabs|January 13, 2010
Preclinical development of monoclonal antibodies: considerations for the use of non-human primatesKathryn Chapman, Nick Pullen, Lee Coney, et al.
Blood|July 19, 2003
Reconstitution of the Epstein-Barr virus-specific cytotoxic T-lymphocyte response following T-cell-depleted myeloablative and nonmyeloablative allogeneic stem cell transplantationSuparno Chakrabarti, Donald W Milligan, Deenan Pillay, et al.
Journal of Neurology|July 27, 2005
The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapyAlasdair J Coles, Amanda Cox, Emmanuelle Le Page, et al.
Journal of Clinical Pharmacology|February 12, 2010
Pharmacokinetics and antibody responses to the CD3 antibody otelixizumab used in the treatment of type 1 diabetesGeoff Hale, Peppy Rebello, Ibrahim Al Bakir, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 30, 2003
Reduced-intensity transplantation with in vivo T-cell depletion and adjuvant dose-escalating donor lymphocyte infusions for chemotherapy-sensitive myeloma: limited efficacy of graft-versus-tumor activityKarl S Peggs, Stephen Mackinnon, Catherine D Williams, et al.
Haematologica|November 4, 2006
Outcomes after myeloablative unrelated donor stem cell transplantation using both in vitro and in vivo T-cell depletion with alemtuzumabPeter A von dem Borne, Floor Beaumont, C W J Ingrid Starrenburg, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 3, 2004
Incidence and outcome of adenovirus disease in transplant recipients after reduced-intensity conditioning with alemtuzumabIrit Avivi, Suparno Chakrabarti, Donald W Milligan, et al.
Blood|April 20, 2004
Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administrationGeoff Hale, Peppy Rebello, Lee R Brettman, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 1, 2004
Favorable effect on acute and chronic graft-versus-host disease with cyclophosphamide and in vivo anti-CD52 monoclonal antibodies for marrow transplantation from HLA-identical sibling donors for acquired aplastic anemiaVikas Gupta, Sarah E Ball, Qi-long Yi, et al.
British Journal of Haematology|December 11, 2002
Respiratory virus infections in transplant recipients after reduced-intensity conditioning with Campath-1H: high incidence but low mortalitySuparno Chakrabarti, Irit Avivi, Stephen Mackinnon, et al.
Pageof 6